文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

[Long-term outcome after photodynamic therapy of persistent central serous chorioretinopathy].

作者信息

Kiskämper Anna, Augstein Maximilian, von Schwarzkopf Christoph, Laich Yannik, Rothaus Kai, Janning Carolin, Pauleikhoff Laurenz, Lange Clemens

机构信息

Augenzentrum am St. Franziskus-Hospital Münster, Hohenzollernring 74, 48145, Münster, Deutschland.

Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.

出版信息

Ophthalmologie. 2025 Aug 23. doi: 10.1007/s00347-025-02311-w.


DOI:10.1007/s00347-025-02311-w
PMID:40848068
Abstract

BACKGROUND AND OBJECTIVE: Persistent central serous chorioretinopathy (CSC) is a complex macular disease that if left untreated can lead to deterioration of visual acuity and impairment of the quality of life. A treatment of choice is photodynamic therapy (PDT), which in studies has been shown to achieve stable functional and morphological results with a short follow-up period. As there are only few studies on the long-term evolution after PDT, this study aims to evaluate the long-term functional and morphological outcomes after PDT. MATERIAL AND METHODS: In this multicenter retrospective cohort analysis, patients with persistent CSC treated with PDT during 2004-2020 were analyzed over a follow-up period of at least 4 years after PDT. In addition to the clinical examination, the results of multimodal imaging techniques such as optical coherence tomography (OCT), OCT angiography, fundus autofluorescence and fluorescein angiography were analyzed. RESULTS: A total of 33 eyes of 31 patients were analyzed over a mean follow-up period of 7.3 ± 3.6 years (4-19 years) after PDT. During the observation period a stable mean visual acuity of 0.41 ± 0.29 logMAR before PDT and 0.39 ± 0.38 logMAR at the last follow-up was observed. The subfoveal subretinal fluid (SRF) decreased significantly from a mean of 153 ± 90 µm (median 137 µm) before PDT to 24 ± 61 µm (median 0 µm) at the last follow-up. Of the 33 eyes 23 showed no evidence of SRF at the last OCT examination. Five eyes developed new choroidal neovascularization during the course of the study, which was treated with intravitreal injections. In a total of nine eyes newly occurring atrophy of the retinal pigment epithelium was detected at the last follow-up. CONCLUSION: In the present study a predominantly stable functional and improved anatomical outcome after PDT was observed over a long observation period of more than 7 years. Further prospective long-term studies with a high level of evidence are required for a better assessment of the safety and functionality of PDT.

摘要

相似文献

[1]
[Long-term outcome after photodynamic therapy of persistent central serous chorioretinopathy].

Ophthalmologie. 2025-8-23

[2]
Interventions for central serous chorioretinopathy: a network meta-analysis.

Cochrane Database Syst Rev. 2015-12-22

[3]
Interventions for central serous chorioretinopathy: a network meta-analysis.

Cochrane Database Syst Rev. 2025-6-16

[4]
Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.

Acta Ophthalmol. 2016-3

[5]
Prescription of Controlled Substances: Benefits and Risks

2025-1

[6]
Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.

Cochrane Database Syst Rev. 2016-12-15

[7]
Aflibercept for neovascular age-related macular degeneration.

Cochrane Database Syst Rev. 2016-2-8

[8]
Surgery for cataracts in people with age-related macular degeneration.

Cochrane Database Syst Rev. 2017-2-16

[9]
Eplerenone and Spironolactone for Chronic Central Serous Chorioretinopathy: A Systematic Review and Meta-Analysis.

Am J Ophthalmol. 2025-6-11

[10]
Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy.

Cochrane Database Syst Rev. 2015-1-7

本文引用的文献

[1]
Three-Year Follow-Up Detecting Choroidal Neovascularization with Swept Source Optical Coherence Tomography Angiography (SS-OCTA) after Successful Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.

Diagnostics (Basel). 2023-8-29

[2]
INCREASING EVIDENCE FOR THE SAFETY OF FOVEA-INVOLVING HALF-DOSE PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.

Retina. 2023-3-1

[3]
Comparative efficacy of treatments for chronic central serous chorioretinopathy: A systematic review with network meta-analyses.

Acta Ophthalmol. 2023-3

[4]
Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care.

Acta Ophthalmol. 2022-11

[5]
3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization.

Sci Rep. 2021-6-24

[6]
Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy.

Graefes Arch Clin Exp Ophthalmol. 2021-4

[7]
Long-Term Effects of Half-Time Photodynamic Therapy on Retinal Sensitivity in Eyes with Chronic Central Serous Chorioretinopathy.

Biomed Res Int. 2020

[8]
Long-Term Efficacy and Safety of Photodynamic Therapy in Patients With Chronic Central Serous Chorioretinopathy.

Ophthalmic Surg Lasers Imaging Retina. 2019-12-1

[9]
Central serous chorioretinopathy: Towards an evidence-based treatment guideline.

Prog Retin Eye Res. 2019-7-15

[10]
Optical Coherence Tomography Angiography for Diagnosis of Choroidal Neovascularization in Chronic Central Serous Chorioretinopathy after Photodynamic Therapy.

Sci Rep. 2019-6-21

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索